DK1302205T3 - Formuleringer med styret frigivelse af makrolidcitratsalte - Google Patents

Formuleringer med styret frigivelse af makrolidcitratsalte

Info

Publication number
DK1302205T3
DK1302205T3 DK02256823T DK02256823T DK1302205T3 DK 1302205 T3 DK1302205 T3 DK 1302205T3 DK 02256823 T DK02256823 T DK 02256823T DK 02256823 T DK02256823 T DK 02256823T DK 1302205 T3 DK1302205 T3 DK 1302205T3
Authority
DK
Denmark
Prior art keywords
macrolide
controlled release
release formulations
citrate salts
macrolides
Prior art date
Application number
DK02256823T
Other languages
Danish (da)
English (en)
Inventor
Hardeep Wadhwa
Original Assignee
Ind Swift Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind Swift Ltd filed Critical Ind Swift Ltd
Application granted granted Critical
Publication of DK1302205T3 publication Critical patent/DK1302205T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
DK02256823T 2001-10-01 2002-10-01 Formuleringer med styret frigivelse af makrolidcitratsalte DK1302205T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1018DE2001 2001-10-01
IN1019DE2001 2001-10-01

Publications (1)

Publication Number Publication Date
DK1302205T3 true DK1302205T3 (da) 2005-08-08

Family

ID=26324885

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02256823T DK1302205T3 (da) 2001-10-01 2002-10-01 Formuleringer med styret frigivelse af makrolidcitratsalte

Country Status (9)

Country Link
US (1) US6642276B2 (fr)
EP (1) EP1302205B1 (fr)
JP (1) JP2003212757A (fr)
AT (1) ATE291922T1 (fr)
BR (1) BR0208526A (fr)
CA (1) CA2405918A1 (fr)
DE (1) DE60203461T2 (fr)
DK (1) DK1302205T3 (fr)
PT (1) PT1302205E (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US20050249786A1 (en) * 2001-09-28 2005-11-10 Solubest Ltd. Hydrophilic dispersions of nanoparticles of inclusion complexes of amorphous compounds
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
WO2004100880A2 (fr) * 2003-05-06 2004-11-25 Nirmal Mulye Formulation a liberation controlee de derives d'erythromycine
EP2529730A1 (fr) * 2003-06-16 2012-12-05 ANDRX Pharmaceuticals LLC. Composition à libération prolongée orale
WO2005004919A2 (fr) * 2003-07-02 2005-01-20 Eurand, Inc. Systemes de liberation prolongee destines a des antibiotiques macrolides
WO2005009364A2 (fr) 2003-07-21 2005-02-03 Advancis Pharmaceutical Corporation Produit antibiotique, utilisation et formulation associees
CA2533292C (fr) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Produit antibiotique, utilisation et formulation correspondantes
CA2533178C (fr) 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Produit antibiotique, son utilisation et sa formulation
US20050049209A1 (en) * 2003-08-06 2005-03-03 Chen Andrew Xian Pharmaceutical compositions for delivering macrolides
WO2005016311A1 (fr) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Pastille robuste
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
EP1663169A4 (fr) 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In Antibiotique, son utilisation et sa formulation
US8168228B2 (en) * 2003-10-17 2012-05-01 Sandoz Ag Antibiotic clarithromycin micropellet compositions
US20050084540A1 (en) * 2003-10-17 2005-04-21 Indranil Nandi Taste masking antibiotic composition
US20050101547A1 (en) * 2003-11-06 2005-05-12 Sadatrezaei Mohsen Stabilized azithromycin composition
AU2005235237A1 (en) * 2004-03-24 2005-11-03 Lupin Limited Clarithromycin extended release formulation
US8188067B2 (en) 2004-04-01 2012-05-29 Teva Pharmaceutical Industries Ltd. Formulations of 6-mercaptopurine
WO2005099665A2 (fr) * 2004-04-01 2005-10-27 Teva Pharmaceutical Industries Ltd. Formulations ameliorees de 6-mercaptopurine
JP2008505124A (ja) 2004-07-02 2008-02-21 アドバンシス ファーマスーティカル コーポレイション パルス送達用錠剤
JP5004236B2 (ja) * 2005-02-09 2012-08-22 キッセイ薬品工業株式会社 口腔内崩壊錠
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US20070087055A1 (en) * 2005-10-14 2007-04-19 David Jan Directly compressible extended release alprazolam formulation
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US20070202164A1 (en) * 2006-02-28 2007-08-30 Hutchison Medipharma Enterprises Limited Andrographis Extract Formulations
WO2007126039A1 (fr) * 2006-04-28 2007-11-08 Shionogi & Co., Ltd. Préparation antibiotique macrolide enrobée
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
EP2030613A1 (fr) * 2007-08-17 2009-03-04 Abbott GmbH & Co. KG Préparation de compositions avec essentiellement des antibiotiques macrolides intégrés non cristallins
CA2721728A1 (fr) * 2008-04-18 2009-10-22 Teva Pharmaceutical Industries Ltd. Traitement d'une maladie intestinale inflammatoire avec de la 6-mercaptopurine
CN101624412B (zh) * 2008-07-10 2012-07-04 刘力 大环内酯类衍生物及其制备和用途
EP2283824B1 (fr) 2009-07-30 2017-04-19 Special Products Line S.p.A. Compositions et formules basées sur des matrices gonflables pour la libération prolongée de médicaments, comme clarithromycin, faiblement solubles
JP2013180961A (ja) * 2012-02-29 2013-09-12 Astellas Pharma Inc Ｗｓ７２７７１３含有固形製剤
EP2671571A1 (fr) 2012-06-05 2013-12-11 Sanovel Ilac Sanayi ve Ticaret A.S. Formulations à libération contrôlée de clarithromycine
CN103776945A (zh) * 2014-01-16 2014-05-07 扬子江药业集团南京海陵药业有限公司 罗红霉素胶囊的质量控制方法
US20170105996A1 (en) 2015-10-16 2017-04-20 Teva Pharmaceutical Industries, Ltd. Treatment of non-alcoholic fatty liver disease or non-alcoholic steatohepatitis with delayed-release 6-mercaptopurine
CN105997929A (zh) * 2016-06-23 2016-10-12 南京华宽信息咨询中心 一种罗红霉素胶囊及其制备方法
CN106580903B (zh) * 2016-11-17 2019-12-13 江苏豪森药业集团有限公司 罗红霉素缓释药物组合物
CN109248155B (zh) * 2018-09-27 2020-08-11 北京鑫开元医药科技有限公司 一种罗红霉素胶囊及其制备工艺

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0188040B1 (fr) * 1985-01-11 1991-08-14 Abbott Laboratories Limited Préparation solide à libération lente
US5457111A (en) * 1991-09-05 1995-10-10 Abbott Laboratories Macrocyclic immunomodulators
US5705190A (en) * 1995-12-19 1998-01-06 Abbott Laboratories Controlled release formulation for poorly soluble basic drugs
US5750510A (en) * 1997-04-04 1998-05-12 Abbott Laboratories 3-descladinose-2,3-anhydroerythromycin derivatives
US6551616B1 (en) * 1997-04-11 2003-04-22 Abbott Laboratories Extended release formulations of erythromycin derivatives
JPH10335732A (ja) * 1997-06-02 1998-12-18 Toshiba Microelectron Corp レーザ用制御回路および制御方法
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
IT1303671B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
SI20150A (sl) * 1999-02-19 2000-08-31 Lek, Tovarna Farmacevtskih In Direktno stisljivi matriks za nadzorovano sproščanje celodnevne doze klaritromicina
TR200000054A2 (tr) * 2000-01-05 2001-08-21 Sanovel İlaç San. Ve Ti̇c. Anoni̇m Şi̇rketi̇ Klaritromisin içeren sürekli salım sağlayan tablet formülasyonları.

Also Published As

Publication number Publication date
DE60203461D1 (de) 2005-05-04
EP1302205B1 (fr) 2005-03-30
US20030077325A1 (en) 2003-04-24
ATE291922T1 (de) 2005-04-15
CA2405918A1 (fr) 2003-04-01
EP1302205A1 (fr) 2003-04-16
BR0208526A (pt) 2004-08-10
US6642276B2 (en) 2003-11-04
JP2003212757A (ja) 2003-07-30
DE60203461T2 (de) 2006-02-09
PT1302205E (pt) 2005-06-30

Similar Documents

Publication Publication Date Title
DK1302205T3 (da) Formuleringer med styret frigivelse af makrolidcitratsalte
EE05400B1 (et) Prasoolderivaadid, neid v?i nende farmatseutiliselt vastuv?etavaid sooli, solvaate v?i derivaate sisaldavad farmatseutilised kompositsioonid, nende kasutamine ning meetodid nende valmistamiseks
NO20020976D0 (no) Retarderte, orale, farmasöytiske administreringsformer
DK1448235T3 (da) Orale, farmaceutiske sammensætninger af 5,8,14-triaza-tetracyclo[10.3.1.0(2,11).0(4.9)]-hexadeca-2(11),3,5,7,9-pentaen med kontrolleret frigivelse
HUP0101237A1 (hu) Elnyújtott kioldódású gyógyszerkészítmények
EE05081B1 (et) Farmatseutilised kompositsioonid, mis sisaldavad 3-aminoasetidiini derivaate, 3-aminoasetidiini derivaadid ja nende valmistamise meetodid
DE60100186D1 (de) Orale pharmazeutische formulierungen von benzimidazolderivaten und verfahren zu ihrer herstellung
AU2002357012A1 (en) Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
AU2002239282A1 (en) Pharmaceutical formulations comprising paclitaxel, derivatives, and pharmaceutically acceptable salts thereof
DE69936002D1 (de) Angepasster löffel zur oralen medikamenten-verabreichung
DK1478339T3 (da) Farmaceutiske formuleringer af antineoplastiske midler, specielt temozolomid, fremgangsmåder til fremstilling og anvendelse heraf
NO20043998L (no) Oral administreringsform for tungtloselige basiske aktive virkestoffer
NO20002977D0 (no) Terapeutisk formulering for administrasjon av tolterodin med kontrollert frigivelse
MXPA03003895A (es) Formulaciones de hidrocodona de liberacion controlada.
EE200300207A (et) Heterotsüklüülalküülpiperidiini derivaadid, nendevalmistamismeetodid ja farmatseutiline kompositsioon
NO20042565L (no) Orale farmasoytiske produkter inneholdende 17 beta-ostradiol-3-lavere alkanoat, fremgangsmater for administrering av disse og fremgangsmater for fremstilling derav
MXPA03002569A (es) Formulaciones de liberacion controlada para administracion oral.
ATA59499A (de) Pharmazeutische, tolperison enthaltende zubereitung zur oralen verabreichung
ATE409474T1 (de) Tryptamin-derivative und analoge verbindungen, und pharmazeutische formulationen daraus
NO20021452D0 (no) Orale kontrollerte frigivelsesformuleringer
NO20016404D0 (no) Naftyridinderivater, fremgangsmåter for deres fremstilling, deres anvendelse og farmasöytiske preparater omfattende disse
HUP0302291A3 (en) Sulfonamide derivatives, process for their preparation and their use for preparation of pharmaceutical compositions
EE200100579A (et) 6-[(arüül- ja heteroarüül)oksü]metüül]naftaleen-2-karboksimiidamiidi derivaadid, nende valmistamineja nende terapeutiline kasutamine
NO20032581D0 (no) Farmasöytisk formulering av gepiron for oral administrering
EE05380B1 (et) FenletanoolamiiniÁkristallivorm,ÁselleÁvalmistamineÁjaÁsedaÁsisaldavadÁfarmatseutilisedÁkompositsioonid